Evan Shereck
Overview
Explore the profile of Evan Shereck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keller M, Hanley P, Chi Y, Aguayo-Hiraldo P, Dvorak C, Verneris M, et al.
Nat Commun
. 2024 Apr;
15(1):3258.
PMID: 38637498
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed...
2.
Abraham R, Basu A, Heimall J, Dunn E, Yip A, Kapadia M, et al.
Clin Immunol
. 2024 Feb;
261:109942.
PMID: 38367737
Severe combined immunodeficiency (SCID) is characterized by a severe deficiency in T cell numbers. We analyzed data collected (n = 307) for PHA-based T cell proliferation from the PIDTC SCID...
3.
Eissa H, Thakar M, Shah A, Logan B, Griffith L, Dong H, et al.
J Allergy Clin Immunol
. 2023 Oct;
153(1):287-296.
PMID: 37793572
Background: The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children in the United States and Canada onto a retrospective multicenter natural history study of hematopoietic cell transplantation (HCT). Objective: We...
4.
Dvorak C, Haddad E, Heimall J, Dunn E, Cowan M, Pai S, et al.
J Allergy Clin Immunol
. 2022 Dec;
151(2):547-555.e5.
PMID: 36456360
Background: Shearer et al in 2014 articulated well-defined criteria for the diagnosis and classification of severe combined immunodeficiency (SCID) as part of the Primary Immune Deficiency Treatment Consortium's (PIDTC's) prospective...
5.
Davila Saldana B, John T, Bonifant C, Buchbinder D, Chandra S, Chandrakasan S, et al.
Blood Adv
. 2021 Oct;
6(2):452-459.
PMID: 34670275
Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is characterized by high levels of EBV predominantly in T and/or natural killer cells with lymphoproliferation, organ failure due to infiltration of tissues...
6.
Shimano K, Narla A, Rose M, Gloude N, Allen S, Bergstrom K, et al.
Am J Hematol
. 2021 Aug;
96(11):1491-1504.
PMID: 34342889
The North American Pediatric Aplastic Anemia Consortium (NAPAAC) is a group of pediatric hematologist-oncologists, hematopathologists, and bone marrow transplant physicians from 46 institutions in North America with interest and expertise...
7.
Howe M, Dowdell K, Kuehn H, Li Q, Hart G, Garabedian D, et al.
J Infect Dis
. 2020 May;
222(7):1170-1179.
PMID: 32386415
Background: Chronic active Epstein-Barr virus (CAEBV) presents with high levels of viral genomes in blood and tissue infiltration with Epstein-Barr virus (EBV)-positive lymphocytes. The pathogenesis of CAEBV is poorly understood....
8.
Burroughs L, Petrovic A, Brazauskas R, Liu X, Griffith L, Ochs H, et al.
Blood
. 2020 Apr;
135(23):2094-2105.
PMID: 32268350
Wiskott-Aldrich syndrome (WAS) is an X-linked disease caused by mutations in the WAS gene, leading to thrombocytopenia, eczema, recurrent infections, autoimmune disease, and malignancy. Hematopoietic cell transplantation (HCT) is the...
9.
Chan A, Leiding J, Liu X, Logan B, Burroughs L, Allenspach E, et al.
Front Immunol
. 2020 Mar;
11:239.
PMID: 32153572
Primary Immune Regulatory Disorders (PIRD) are an expanding group of diseases caused by gene defects in several different immune pathways, such as regulatory T cell function. Patients with PIRD develop...
10.
Shereck E, Day N, Awasthi A, Ayello J, Chu Y, McGuinn C, et al.
Innate Immun
. 2019 May;
25(5):294-304.
PMID: 31068047
Unrelated cord blood (CB) is an excellent alternative as an allogeneic donor source for stem cell transplantation. CB transplantation is associated with lower incidence of severe acute graft versus host...